Stay updated with breaking news from Completed Enrollment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
01.08.2023 - WAKIX (pitolisant) Net Revenue Increased ~25% Year-over-Year to $134.2 Million for Second Quarter 2023 Average Number of Patients on WAKIX Increased by ~350 Sequentially to ~5,450 for Second Quarter 2023 Exited Second Quarter 2023 With ~5,600 ...
01.03.2023 - - Achieved $31.3 Million in Net Revenue from Sales of COSELA (trilaciclib) for Full Year 2022, Representing 182% Growth Over 2021; Provided 2023 Net COSELA Revenue Guidance of $50 to $60 Million - - Announced Top Line Results from Pivotal Phase 3 ...
Interim Analysis in Phase 2 CANAL Trial Showed Primary Efficacy Endpoint of Cough Reduction in Idiopathic Pulmonary Fibrosis was Highly Statistica...